MACD recently crossed. Priced bounced off the ichimoku cloud. Squeeze momentum & Awesome oscillator looking bullish.
After bottoming out in early December at the 200 sma it has made higher lows and the 9ema crossed the 20 ema. In addition both EMAs crossed the 50 sma showing us that the short and medium term trends are bullish. This will bounce around a bit in the $5.70-$5.09 range as it builds a new base before moving to new highs. It will see some resistance at $6.33 First...
XERS recently bounced off its 200 MA and currently has some favorable signals. The MACD is crossing and the RSI is rising but still on the cool side. Looking at the Volume Indicator (Fixed Range) Sept 1 to Current you can see that the POC line in red (point of control) shows us that most of the trading volume has been at the current level and 70% of XERS trading...
XERS has found support once again at the ascending trendline from March 2020, the trendline also coincides with the 2 VWAPs from what I would consider the significant YTD lows, as well as the very important $4.00 level. I have been long since August ($3.54) and I am looking to add as close to $4.00 as possible because I believe the stock moves higher from here.
NASDAQ:XERS shows resistance to price correction and stays on the uptrend.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.
Looking for a break out above $5.15 which is the .618 fib level. First target $5.89
Alert set for a break above the 200ma and $5.00 level. Highly speculative with high Risk| Reward . Company profile Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke...
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.